Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery

In this Special Series, kidney cancer (KC) experts describe how recent advances can be integrated into clinical management strategies and focus on important future priorities, including understanding mechanisms by which KC develops and becomes resistant to standard therapies.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news

Related Links:

ConclusionsThere are several well-described hereditary RCC syndromes, as well as recently identified ones, for which the full clinical spectrum is yet to be defined. In the new era of precision medicine, identification of these syndromes may play an important role in management and systemic treatment selection.Patient summaryThis review covers updates in the diagnosis and management of familial kidney cancer syndromes. We describe updates in testing and management of the most common syndromes such as von Hippel-Lindau, and hereditary leiomyomatosis and renal cell carcinoma. We also provide insights into recently described ...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Integrating 3D printing technology into presurgical planning for hip joint...Read more on AuntMinnie.comRelated Reading: 3D printing bolsters surgery for multiple rib fractures AR, 3D printing aid presurgical planning for kidney cancer 3D printing gives pediatric heart surgery a boost 3D printing boosts efficiency of rib fracture repair 3D-printed hips may improve complex fracture diagnosis
Source: Headlines - Category: Radiology Source Type: news
THE STUDY BY Fukazawa et al.1 was a retrospective analysis of 56 renal cell cancer patients who underwent nephrectomy with inferior vena cava (IVC) thrombectomy from 2014 –2017 at the University of Washington Medical Center. The authors sought to quantify growth of IVC tumor burden during the interval between imaging and surgical resection in order to develop recommendations for optimal timing of imaging and determine whether tumor thrombus level as defined by the Mayo Clinic criteria at the time of surgery correlated with the risk of perioperative pulmonary embolism (PE).
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Tags: Editorial Source Type: research
Objectives: The aim of this study was to evaluate the correlation of various clinicopathological variables with positive surgical margins (PSMs) in renal cell cancer (RCC) patients after nephron-sparing surgery (NSS). Methods: A systematic search of PubMed, EMBASE, Web of Science, and China National Knowledge Infrastructure (CNKI) was performed to identify studies that compared PSMs with negative surgical margins (NSMs) and were published up to December 2018. Outcomes of interest included perioperative and postoperative variables, and the data were pooled by odds ratios (ORs) / standard mean differences (SMD) with 95% con...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conditions:   Clear Cell Renal Cell Carcinoma;   Locally Advanced Unresectable Renal Cell Carcinoma;   Stage III Renal Cell Cancer AJCC v8 Intervention:   Drug: Cabozantinib Sponsors:   Emory University;   Exelixis Not yet recruiting
Source: - Category: Research Source Type: clinical trials
as Oermann Fan With 15 drugs currently approved for the treatment of metastatic renal cell carcinoma (mRCC) and even more combination regimens with immunotherapy on the horizon, there remains a distinct lack of molecular biomarkers for therapeutic efficacy. Our study reports on real-world clinical outcomes of mRCC patients from a tertiary academic medical center treated with empirically selected standard-of-care therapy. We utilized the Stanford Renal Cell Carcinoma Database (RCCD) to report on various outcome measures, including overall survival (OS) and the median number of lines of targeted therapies received...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Abstract Renal cell carcinoma (RCC) is the second most lethal urinary cancer. RCC is frequently asymptomatic and it is already metastatic at diagnosis. There is an urgent necessity for RCC specific biomarkers selection for diagnostic and prognostic purposes. In present study, we applied liquid chromatography - mass spectrometry (LC-MS) based metabolomics to analyze urine samples of 100 RCC, 34 benign kidney tumors and 129 healthy controls. Differential metabolites were analyzed to investigate if urine metabolites could differentiate RCC from non-RCC. A panel consisting of 9 metabolites showed the best predictive ability f...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsTimely follow-up of abnormal results remains challenging in an EHR-based integrated health care delivery system. Strategies improving provider EHR message box management and leveraging health information technology (eg, flagging abnormal eGFR results), making organizational/staffing changes (eg, increasing the role of nurses in managing laboratory results), and boosting patient engagement through better patient portals may improve test follow-up.
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Condition:   Kidney Cancer Interventions:   Drug: Perflutren lipid microsphere;   Drug: Sulfur hexafluoride lipid microspheres Sponsor:   UNC Lineberger Comprehensive Cancer Center Not yet recruiting
Source: - Category: Research Source Type: clinical trials
This research provides the first evidence of CDK5 in ccRCC prognosis and correlation with different p21 expression in overall survival (OS) analysis.
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
More News: Cancer | Cancer & Oncology | Health | Kidney Cancer | Urology & Nephrology